Printer Friendly

NovaDel announces end of licence deals with Talon, Par for ondansetron oral spray product.

M2 PHARMA-January 23, 2012-NovaDel announces end of licence deals with Talon, Par for ondansetron oral spray product(C)2012 M2 COMMUNICATIONS

23 January 2012 - NovaDel Pharma Inc (OTCBB:NVDL), a US company developing oral spray formulations for a range of marketed pharmaceuticals, on Friday announced the termination of certain licence agreements with Par Pharmaceutical Companies Inc (NYSE:PRX) and Talon Therapeutics Inc (OTCBB:TLON) related to the development and commercialisation of the company's ondansetron HCl oral spray product.

The termination of the accords has come into effect since 16 January 2012. As a result, all rights to develop and commercialise the product were returned to NovaDel Pharma in exchange for Talon's right to receive certain royalty payments related to the product.

With the termination of the agreements, NovaDel Pharma regains control of the product within US and Canada, a step the company estimates would better position it for a potential strategic transaction.

NovaDel Pharma has two FDA-approved marketed products. These are NitroMist for the treatment of angina and Zolpimist for the treatment of insomnia. Its lead product candidate, Duromist, is being developed for the treatment of erectile dysfunction.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2012 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jan 23, 2012
Words:199
Previous Article:RBCC looks for investment bankers for capital to finance n3D acquisition.
Next Article:Covidien names head of Vascular Therapies business.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters